Showing results (1631-1640 of 1,642) with videos related to

Sort By:
Pageof 165
The Lancet. HIV|September 2, 2019
Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trialMartin R Gaudinski, Katherine V Houser, Nicole A Doria-Rose, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
European Biophysics Journal : EBJ|April 21, 2021
Reproducibility and accuracy of microscale thermophoresis in the NanoTemper Monolith: a multi laboratory benchmark studyBlanca López-Méndez, Bruno Baron, Chad A Brautigam, et al.
Eclinicalmedicine|July 5, 2022
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trialKatherine V Houser, Martin R Gaudinski, Myra Happe, et al.
Science Translational Medicine|April 19, 2023
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adultsAlicia T Widge, Amelia R Hofstetter, Katherine V Houser, et al.
Nature Medicine|February 4, 2022
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trialKatherine V Houser, Grace L Chen, Cristina Carter, et al.
The Lancet. HIV|May 23, 2025
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adultsRichard L Wu, Katherine V Houser, Martin R Gaudinski, et al.
The Lancet. Infectious Diseases|August 6, 2023
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trialBetty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, et al.
Lancet (London, England)|January 28, 2023
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trialMelinda J Hamer, Katherine V Houser, Amelia R Hofstetter, et al.
NPJ Vaccines|September 17, 2024
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccineJoseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, et al.
Pageof 165